Geriatric Nursing Comprehensive Review: Mental Health, Neurocognitive Disorders, and Clinical Care

Transition to Long-Term Care and Resident Autonomy

• Facilitating Admission and Preventing Relocation Stress Syndrome:

  • Orientation and Welcome: Greet the newly admitted resident by their preferred name, introduce essential care team members, assign a dedicated primary nurse or consistent certified nursing assistant, and provide an unhurried, comprehensive tour of the unit and communal spaces.
  • Personalization of Environment: Encourage the resident and family to bring familiar personal belongings from home, such as family photographs, personal bedspreads, favorite furniture pieces, wall art, and familiar clothing, to transform an institutional room into a personalized living space.
  • Care Plan Integration: Involve the resident directly in care plan conferences; actively solicit their baseline routines, sleep patterns, dietary likes and dislikes, and long-standing habits rather than imposing rigid facility schedules.
  • Social and Peer Integration: Pair the resident with a welcoming, cognitively intact peer mentor who shares similar interests; introduce them gradually to communal dining and activity groups without overwhelming them.
  • Family Engagement: Support continuous family involvement by establishing open communication, flexible visiting hours, and educating loved ones on signs of relocation stress syndrome (e.g., anxiety, depression, confusion, social withdrawal).

• Promoting Resident Autonomy and Personal Control:

  • Decision-Making Opportunities: Offer realistic daily choices whenever possible, including clothing selection, bathing time, choice of meals or snacks, and preferred wake-up and bedtimes.
  • Respect for Privacy and Boundaries: Knock before entering the resident's room, wait for permission to enter, and maintain privacy during personal care and clinical assessments.
  • Empowerment in Clinical Care: Explain all nursing procedures before execution, ask for resident assent, and respect their right to refuse or modify non-emergent interventions.
  • Access to Personal Possessions: Ensure assistive devices (glasses, hearing aids, dentures, mobility aids) and personal items are placed within easy reach to maintain functional self-reliance.

Clinical Depression and Anxiety in Older Adults

• Etiology and Predisposing Factors:

  • Chronic Medical Illness and Pain: Co-morbidities such as stroke, Parkinson disease, cardiovascular disease, diabetes mellitus, osteoarthritis, and chronic pain syndromes alter neurobiology and deplete functional capacity.
  • Psychosocial Losses: Accumulation of significant losses, including the death of a spouse, siblings, and lifelong peers; loss of independent living; driving cessation; and loss of occupational identity.
  • Neurobiological Changes: Age-associated vascular alterations, cerebral white matter hyperintensities, and disruptions in central monoamine neurotransmitter pathways (serotonin, norepinephrine, dopamine).
  • Sensory Deprivation: Progressive visual or auditory impairment leading to communicative isolation, cognitive strain, and environmental disorientation.

• Signs and Symptoms of Clinical Depression:

  • Atypical Geriatric Presentation: Older adults often deny subjective sadness or dysphoria, presenting instead with "depression without sadness."
  • Somatic and Vegetative Manifestations: Vague somatic complaints, gastrointestinal disturbances, fatigue, psychomotor retardation or agitation, severe anorexia, and unintentional weight loss.
  • Cognitive Symptoms (Pseudodementia): Subjective memory complaints, executive dysfunction, impaired concentration, and frequent answers of "I don't know" during cognitive testing (contrasting with the confabulation often observed in primary dementia).
  • Anhedonia and Apathy: Profound loss of pleasure or interest in previously enjoyed activities, social withdrawal, flat affect, and neglect of personal hygiene.

• Clinical Monitoring Parameters in Depressive and Anxiety States:

  • Nutritional and Fluid Intake: Daily monitoring of meal percentages, weekly weights, and surveillance of fluid consumption to prevent dehydration and malnutrition.
  • Sleep Architecture: Documentation of sleep patterns, noting sleep onset latency, frequent nocturnal awakenings, or early morning awakening (terminal insomnia).
  • Somatic and Behavioral Fluctuations: Observation of agitation, pacing, wringing of hands, catastrophic reactions, or severe lethargy.
  • Medication Adherence and Side Effects: Monitoring for compliance, emergence of adverse anticholinergic effects, orthostatic blood pressure drops, or serotonergic complications.

• Suicide Assessment and Crisis Intervention:

  • High-Risk Demographics: Older adults—particularly older Caucasian males aged $85$ years and older—exhibit the highest suicide completion rates. They frequently use highly lethal means (firearms), provide fewer explicit verbal warnings, and have a lower ratio of attempts to completions.
  • Level of Concern: Any verbalization of suicidal intent, passive death wishes (e.g., "I wish I wouldn't wake up," "Everyone would be better off without me"), sudden calm after deep depression, or giving away prized possessions constitutes a medical and psychiatric emergency.
  • Immediate Nursing Actions:
  • Directly and non-judgmentally question the resident: "Are you having thoughts of harming or killing yourself? Do you have a specific plan or method?"
  • Institute immediate, continuous one-on-one ($1:1$) visual observation.
  • Remove potential environmental hazards (sharps, belts, cords, medications, plastic bags).
  • Notify the attending physician, psychiatric consultation team, and administration immediately.
  • Document all resident statements verbatim, behavioral observations, and safety interventions enacted.

Mental Status and Baseline Behavioral Assessments

• Causes of Uncharacteristic Behavior and Baseline Deviations:

  • Acute Systemic Infections: Urinary tract infections (UTIs), pneumonia, sepsis, and cellulitis frequently trigger sudden mental status alterations before fever or localized symptoms appear.
  • Medication Toxicity and Polypharmacy: Adverse drug reactions, drug-drug interactions, and high anticholinergic burden disrupt central nervous system homeostasis.
  • Metabolic and Electrolyte Derangements: Hyponatremia, hypercalcemia, hypoglycemia, hyperglycemia, acute renal failure, and hepatic dysfunction.
  • Hypoxia and Perfusion Deficits: Exacerbations of congestive heart failure, chronic obstructive pulmonary disease (COPD), acute coronary syndrome, and transient ischemic attacks.
  • Unrelieved Pain and Sensory Overload: Silent myocardial infarction, acute abdominal pathology, fractures, sensory deprivation, or extreme environmental overstimulation.
  • Physical Discomfort: Fecal impaction, acute urinary retention, dehydration, and uncorrected sensory deficits (missing spectacles or dead hearing aid batteries).

• Steps and Components of a Mental Status Assessment:

  • Baseline Establishment: Obtain history from family, caregivers, and medical records to establish pre-morbid cognitive and functional baselines.
  • Level of Consciousness and Alertness: Evaluate whether the patient is alert, lethargic, obtunded, stuporous, or comatose using tools such as the Richmond Agitation-Sedation Scale (RASS).
  • General Appearance and Behavior: Observe grooming, posture, facial expressions, speech tempo, eye contact, and motor activity.
  • Orientation Testing: Assess orientation across four spheres: person, place, time, and situation.
  • Registration and Memory: Administer immediate recall tests (e.g., repeating three unrelated words) and delayed recall assessments ($5$ minutes later).
  • Attention and Calculation: Assess working memory and focus through serial sevens (subtracting $7$ sequentially from $100$) or spelling the word "WORLD" backwards.
  • Language and Executive Function: Assess comprehension, naming of everyday objects, repeating complex phrases, following a three-step command, and copying overlapping figures (e.g., intersecting pentagons in the MMSE or clock-drawing in the Mini-Cog).
  • Standardized Assessment Instruments: Utilize validated tools such as the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Mini-Cog, and Geriatric Depression Scale (GDS).

Management of Clinical Depression: Pharmacology and Nursing Care

• Classes of Antidepressants Used in Older Adults:

  • Selective Serotonin Reuptake Inhibitors (SSRIs): First-line therapy due to favorable safety profiles. Common agents include Sertraline, Escitalopram, and Citalopram (note: Citalopram should be capped at $20\,mg/day$ in older adults due to risk of QT-interval prolongation). Adverse effects include nausea, gastrointestinal bleeding, sexual dysfunction, Syndrome of Inappropriate Antidiuretic Hormone (SIADH) resulting in hyponatremia, and Serotonin Syndrome.
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Effective for co-occurring depression and chronic neuropathic pain. Common agents include Venlafaxine and Duloxetine. Adverse effects include hypertension, tachycardia, dry mouth, nausea, and diaphoresis.
  • Atypical Antidepressants:
  • Mirtazapine: Highly beneficial for frail older adults with severe weight loss and insomnia due to prominent side effects of sedation and appetite stimulation.
  • Bupropion: Useful for apathy and fatigue; does not cause sexual dysfunction or significant sedation. Contraindicated in seizure disorders and eating disorders.
  • Tricyclic Antidepressants (TCAs): Generally avoided in older adults (identified on the Beers Criteria). Agents such as Amitriptyline and Imipramine carry significant risks of orthostatic hypotension, cardiac conduction abnormalities, urinary retention, severe constipation, confusion, and anticholinergic delirium. Secondary amines (Nortriptyline) are comparatively less toxic if a TCA is mandatory.
  • Monoamine Oxidase Inhibitors (MAOIs): Rarely prescribed due to dangerous drug interactions and dietary restrictions (tyramine ingestion triggering fatal hypertensive crisis).

• Nursing Interventions for Pharmacological Adverse Effects:

  • Orthostatic Hypotension Management: Measure lying, sitting, and standing blood pressures; instruct the patient to dangle legs over the bedside before standing; encourage slow transitions; ensure adequate hydration.
  • Anticholinergic Relief: Offer frequent sips of water, ice chips, or sugar-free hard candy for xerostomia; monitor bowel habits, encourage dietary fiber and adequate fluids, and administer prescribed stool softeners for constipation; palpate the suprapubic area to detect urinary retention.
  • Hyponatremia Surveillance: Monitor serum sodium levels regularly; assess for confusion, lethargy, muscle cramps, and unsteady gait.
  • Gastrointestinal Distress: Administer medications with or immediately following meals to mitigate nausea.

• Patient and Caregiver Education on Antidepressant Pharmacotherapy:

  • Therapeutic Onset: Emphasize that therapeutic effects are not immediate; initial symptomatic improvement typically requires $2$ to $4$ weeks, with full clinical efficacy taking $6$ to $8$ weeks or longer.
  • Strict Medication Adherence: Explain that medication must be taken daily as prescribed, even when feeling improved; warn against abrupt discontinuation, which triggers antidepressant discontinuation syndrome (flu-like symptoms, dizziness, paresthesia, electric shock sensations, insomnia).
  • Black Box Warning and Mood Monitoring: Instruct caregivers and patients to watch for paradoxical increases in anxiety, agitation, irritability, or emergence of suicidal thoughts, particularly during the first few weeks of therapy or following dosage adjustments.
  • Management of Side Effects: Educate on self-care measures for dry mouth, constipation, and postural dizziness; emphasize avoiding over-the-counter herbal preparations (e.g., St. John's Wort) due to severe serotonin syndrome risks.

• Non-Pharmacological Interventions for Depression:

  • Structured Physical Exercise: Encourage regular aerobic exercise, such as daily walking groups or seated chair aerobics, which stimulate endogenous endorphin and neurotransmitter release.
  • Cognitive Behavioral Therapy (CBT) and Psychotherapy: Goal-oriented psychotherapy addressing negative cognitive schemas and maladaptive thought patterns.
  • Reminiscence and Life Review Therapy: Facilitate structured discussions recalling past successes, resilience strategies, and meaningful life milestones to promote life integration and self-worth.
  • Bright Light Therapy (Phototherapy): Daily morning exposure to broad-spectrum light ($10,000\,lux$) to regulate circadian rhythms and improve seasonal or chronic depressive symptoms.
  • Social and Creative Engagement: Structured socialization, pet therapy (animal-assisted interventions), music therapy, and art therapy to enhance sensory engagement and decrease isolation.

Cognitive Disorders: Delirium vs. Dementia

• Differential Diagnosis: Delirium versus Dementia:

• Reversibility Distinction: Delirium is the acute, rapid-onset neurocognitive disorder that resolves when the underlying medical condition is identified and treated.

• Etiologies of Delirium in Older Adults (The DELIRIUM Mnemonic):

  • D - Drugs: Anticholinergics, sedatives, hypnotics, opioids, polypharmacy, drug withdrawal (alcohol, benzodiazepines).
  • E - Electrolyte & Metabolic Disturbance: Dehydration, hyponatremia, hypernatremia, hypoglycemia, hypercalcemia, uremia, hepatic dysfunction.
  • L - Lack of Drugs / Pain: Uncontrolled acute pain, sudden cessation of baseline medications.
  • I - Infection: Urinary tract infections, pneumonia, sepsis, COVID-19, wound infections.
  • R - Reduced Sensory Input: Hearing loss, visual impairment, sensory deprivation or profound sensory overload in intensive care units.
  • I - Intracranial Pathology: Stroke, transient ischemic attack, subdural hematoma, meningitis, encephalitis.
  • U - Urinary Retention and Fecal Impaction: Acute bladder distention, severe chronic constipation.
  • M - Myocardial & Pulmonary: Myocardial infarction, congestive heart failure exacerbation, hypoxia, hypercapnia, pulmonary embolism.

• The Four Major Types of Dementia:

  • 1. Alzheimer Disease (AD): The most prevalent dementia etiology ($60\%$ to $80\%$ of cases). Characterized by extracellular beta-amyloid plaques and intracellular neurofibrillary tau tangles. Features prominent early short-term memory loss, followed by aphasia, apraxia, agnosia, executive dysfunction, and eventual motor impairment.
  • 2. Vascular Dementia: Second most common form; caused by ischemic or hemorrhagic cerebrovascular disease (infarctions, microvascular white matter lesions). Classically presents with an abrupt, "stepwise" cognitive decline, prominent early executive dysfunction, focal neurological deficits (e.g., unilateral weakness, gait changes), and vascular risk factors (hypertension, hyperlipidemia, stroke).
  • 3. Lewy Body Dementia (Dementia with Lewy Bodies - DLB): Characterized by abnormal intraneuronal alpha-synuclein protein aggregates (Lewy bodies). Clinical triad features: spontaneous motor Parkinsonism (rigidity, resting tremor, bradykinesia), detailed and recurrent visual hallucinations, and marked cognitive fluctuations in attention and alertness. Patients exhibit extreme neuroleptic sensitivity.
  • 4. Frontotemporal Dementia (FTD / Pick Disease): Characterized by progressive neuronal degeneration of the frontal and temporal lobes. Presents earlier than Alzheimer disease (typically age $45$ to $65$). Hallmarks include dramatic personality alterations, disinhibition, loss of social tact, apathy, hyperorality, repetitive compulsive behaviors, and progressive language impairment (primary progressive aphasias).

• Genetic and Congenital Links:

  • Down Syndrome (Trisomy 21): The congenital condition intimately associated with the development of Alzheimer disease. The amyloid precursor protein (APP) gene is located on chromosome $21$. The presence of three copies of chromosome $21$ leads to accelerated overexpression and deposition of beta-amyloid in brain tissue, resulting in characteristic neuropathological Alzheimer changes in virtually all individuals with Down syndrome by age $40$.

• Pharmacological Management to Slow Dementia Progression:

  • Cholinesterase Inhibitors: Inhibit the enzyme acetylcholinesterase, thereby increasing acetylcholine concentrations at neuronal synapses to stabilize cognitive function in mild-to-moderate dementia.
  • Donepezil: Once-daily dosing; indicated across mild, moderate, and severe Alzheimer disease.
  • Rivastigmine: Available as oral capsules and a transdermal patch (which minimizes gastrointestinal adverse effects).
  • Galantamine: Twice-daily or extended-release once-daily formulation.
  • Adverse Effects: Gastrointestinal hypermotility (nausea, vomiting, diarrhea), anorexia, weight loss, bradycardia, syncope, and insomnia.
  • N-Methyl-D-Aspartate (NMDA) Receptor Antagonists:
  • Memantine: Indicated for moderate-to-severe Alzheimer disease. Regulates excessive pathological glutamate transmission, protecting neurons from excitotoxicity.
  • Adverse Effects: Dizziness, headache, confusion, and constipation.
  • Combination Therapy: Formulations combining Donepezil and Memantine (e.g., Namzaric) provide dual mechanisms of action for moderate-to-severe stages.

• Nursing Interventions for Patients Afflicted with Dementia:

  • Safety and Environmental Adaptation: Ensure a hazard-free environment with clear walkways, nonskid flooring, adequate non-glare lighting, nightlights, and secured exits with wander-management alert systems.
  • Communication Strategies: Speak calmly in low, reassuring tones; maintain eye contact; use clear, short sentences; ask simple questions requiring single-concept responses; allow ample time for the patient to process and formulate answers.
  • Routine and Predictability: Maintain a consistent daily routine, consistent caregiver assignments, and familiar room layout to minimize catastrophic stress and confusion.
  • Reality Orientation vs. Validation Therapy: Use reality orientation gently in early dementia; in moderate-to-severe dementia, employ Validation Therapy—respecting and acknowledging the patient's feelings and perceived reality rather than arguing, confronting, or trying to logically reorient them.
  • Managing Behavioral Disturbances: When agitation, pacing, or sundowning occurs, avoid physical or chemical restraints; identify underlying physical needs (hunger, pain, full bladder); use gentle distraction, soothing music, or redirect the individual toward a quiet, familiar activity.
  • Nutritional Support: Offer finger foods if sitting through meals is difficult; eliminate table clutter; provide high-calorie, nutrient-dense foods; supervise swallowing to prevent aspiration.

• Caregiver Support and Respite Services:

  • Respite Care Definition: Specialized temporary, short-term relief care provided to an individual with chronic illness or dementia, designed to give the primary family caregiver a planned break from the continuous physical and emotional demands of caregiving.
  • Delivery Formats: Available through adult day health centers, in-home respite companion services, or temporary short-term stays in an assisted living or skilled nursing facility.
  • Caregiver Health Outcomes: Prevents caregiver burnout, clinical depression, chronic health decline, and premature institutionalization of the patient.

Substance Use Disorders in Older Adults

• Signs, Symptoms, and Manifestations of Alcohol Use Disorder:
  • Physical Indicators: Unexplained frequent falls, recurrent fractures, unexplained bruises or soft tissue injuries, neglected personal hygiene, poor nutritional status, cognitive impairment, tremors, flushed skin, spider angiomas, and liver function abnormalities.
  • Behavioral and Social Changes: Progressive social withdrawal, hostility, defensiveness when questioned about drinking, loss of interest in hobbies, secretive behavior, empty alcohol bottles concealed around the living environment, and legal or financial difficulties.
  • Cognitive and Affective Changes: Acute memory lapses, blackouts, impaired concentration, fluctuating confusion often misattributed to primary dementia, sleep fragmentation, and worsening depression or anxiety.
  • Pharmacodynamic Alterations: Age-related decreases in total body water, diminished hepatic enzyme metabolism, and reduced lean muscle mass result in higher blood alcohol concentrations per unit consumed, increasing sensitivity to alcohol.
  • High-Risk Medication Interactions: Concurrent alcohol ingestion with CNS depressants (sedatives, opioids), antihypertensives, warfarin, or acetaminophen increases the risk of falls, fatal respiratory depression, gastrointestinal hemorrhage, and hepatic toxicity.
  • Clinical Assessment Tools: Screen using geriatric-specific assessment instruments such as the Michigan Alcoholism Screening Test – Geriatric Version (MAST-G) or the CAGE questionnaire adapted for older adults.